Researchers from the Weizmann Institute, together with partners from Boston and France, have for the first time found a neurological syndrome resulting from a deficiency in a lncRNA gene called "Chaser" – a breakthrough in diagnosing rare diseases
A new genetic syndrome caused by a defect in a non-protein-coding gene has been discovered. The journey to its discovery spanned continents and relied on collaborative databases that offer new hope in the digital age.
Emma Broadbent was born nine years ago in Dallas with unique facial features. From birth, she suffered from muscle weakness and respiratory distress and spent the first weeks of her life in the intensive care unit. Doctors who were unfamiliar with her illness referred her for exome sequencing – a genetic diagnostic procedure that has become common in recent years, including in Israel. This test focuses on the 1% of DNA that contains the protein-coding regions, as these are responsible for most known genetic diseases. However, this test turned up nothing, and Emma continued to suffer from developmental delay and seizures.
Desperate, the parents added the toddler to a network of undiagnosed diseases (, the journey of Weizmann Institute of Science scientists and their colleagues from around the world unfolded until the groundbreaking discovery of the first genetic disease caused by the lack of a copy of a gene that does not code for protein. "Most genetic diagnoses today still ignore lincRNA," says Prof. Olitsky of the Institute's Departments of Immunology and Biological Regeneration and Molecular Neurobiology. "The study emphasizes how important it is to continue the search for the cause of mysterious diseases even among the thousands of genes that do not code for proteins."
The French Knot and the Golden Rule
After the initial connection was made in 2019, researchers around the world began monthly Zoom calls with Brian Broadbent, Emma’s devoted father. The scientists stressed to him the difficulty of learning from a single case, but a major breakthrough came in 2021, when an email arrived from a French research group that had stumbled upon another child who was missing a copy of the gene. A year later, a third case was found in France, and while the cases initially seemed unrelated, a fateful Zoom call changed the picture.
"The conversation was attended by the researchers and the children's families, and we had the help of a postdoctoral fellow from France who worked in Boston who could translate from French to English," explains Prof. Olitsky. "The first time the families saw each other, they immediately recognized that their children had similar neurological characteristics and physical resemblance. Laboratory tests showed that, as we saw in mice, high levels of CHD2 accumulate in the children's cells. MRI scans showed that in the first years of the children's lives, there is a worsening damage to the white matter in the brain, which is responsible for refining and accurately transmitting signals between nerve cells. Now each family has a diagnosis - a syndrome of mental retardation and epilepsy caused by a missing copy of the Chaser gene - and they also have a connection to other families dealing with the disease. And yet, there will be no happy ending to the story until a treatment is found."
Even before the new syndrome was discovered, it was already known that a deficiency in the CHD2 protein was linked to cases of autism and epilepsy. Now it has become clear that excess production of the protein also leads to the disease, which is even more severe, as children suffering from it are confined to wheelchairs, unable to communicate verbally or feed themselves. The new discovery made it clear to researchers that the protein is a clear case of the "Goldilocks principle" - like the heroine of the children's story Goldilocks and the Three Bears who chooses porridge that is neither too hot nor too cold, levels of the CHD2 protein must also be maintained within a defined range to ensure normal development, and any deviation from this range could be fatal. This principle is not unique to CHD2, and in recent years more and more essential proteins have been discovered whose levels undergo precise regulation.
Why is this a problem? Because it is challenging to find a treatment that can precisely adjust protein levels. "We still don't have a solution for the new disease, but for the syndrome caused by a deficiency in the expression of CHD2, we are developing a treatment that causes partial blocking of Chaser," says Prof. Olitsky. "The treatment actually causes the RNA transcribed from the Chaser and CHD2 genes to fuse into a single molecule. In the fused state, Chaser is less active and more CHD2 protein is produced. Today, most people with epilepsy are treated with anticonvulsant drugs rather than with treatments that target the root of the problem. Discovering the genetic cause of epilepsy syndromes could enable more targeted treatments in the future."
The study also included Dr. Kevin Rickin, Dr. Bertrand Isidore, Dr. Elisa Pengam, Dr. Stéphane Bizzot and Prof. Benjamin Konya from the University of Nantes, France; Dr. Nicolas Chetron and Prof. Damien Snellaville from the University of Lyon 1, France; Dr. Kay-Marie Lamar, Miriam S. Aziz, Dr. Esther Yoon and Prof. Gemma L. Carville from Northwestern University, Chicago; Pauline Monin from the Hospices Civils de Lyon University Hospital, France; Melanie O'Leary, Dr. Julia K. Goodrich, Dr. Kieran W. Grimalda, Dr. Elena England, Ben Weisbord, Dr. François Aga, Prof. Daniel G. MacArthur and Prof. Anne O'Donnell-Lurie of the Broad Institute of MIT and Harvard in Cambridge, Massachusetts; Prof. Carlos A. Bacchino, Prof. David R. Murdock, Prof. Hongzhang Dai, Prof. Jill A. Rosenfeld, Prof. Lisa T. Emerick, and Prof. Shmika Katkar of Baylor College of Medicine, Houston, Texas; Yael Serosi of the Institute's Department of Immunology and Regenerative Biology; and Dr. Saima Kayani of the University of Texas Southwestern Medical Center in Dallas.
More on this subject on Hayadan.com - Science news: